Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers

Patent metadata

Field	Value
Publication number	US-10519504-B2
Application number	US-77790210-A
Country	US
Kind code	B2
Filing date	May 11, 2010
Priority date	May 11, 2009
Publication date	Dec 31, 2019
Grant date	Dec 31, 2019

Abstract

Methods and formulations for treating oncological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.

First claim

The invention claimed is:

1. A method for treating an oncological disorder in a mammal having the oncological disorder, consisting of administering to the mammal a therapeutically effective amount of a composition consisting of 0.001% to 30% w/w of Coenzyme Q10 and one or more pharmaceutically acceptable carriers, wherein the Coenzyme Q10 is in the oxidized form and has a purity between 95% and 100%, thereby treating the oncological disorder, wherein the oncological disorder is not melanoma.

2. The method of claim 1 , wherein the composition is formulated for delivery of the oxidized form of the Coenzyme Q10 to the mammal.

3. The method of claim 1 , wherein the Coenzyme Q10 has a purity between 98% and 100%.

4. The method of claim 3 , wherein the Coenzyme Q10 has a purity of at least 99.5%.

5. The method of claim 1 , wherein the Coenzyme Q10 has one or more properties selected from the group consisting of water content less than 0.2%; residue on ignition less than 0.2%; and heavy metal content less than 0.002%.

6. The method of claim 1 , wherein said mammal is human.

7. The method of claim 1 , wherein said oncological disorder is responsive to treatment with Coenzyme Q10 or metabolites thereof.

8. The method of claim 1 , wherein the oncological disorder is selected from the group consisting of a leukemia, a lymphoma, a carcinoma, and a sarcoma.

9. The method of claim 1 , wherein the oncological disorder is selected from the group consisting of liver cancer, pancreatic cancer, breast cancer, prostate cancer, bone cancer, squamous cell carcinoma, basal cell carcinoma, colon cancer, lung cancer, brain cancer, and ovarian cancer.

10. The method of claim 1 , wherein said oncological disorder is an aggressive oncological disorder.

11. The method of claim 10 , wherein the aggressive oncological disorder is selected from the group consisting of pancreatic carcinoma, hepatocellular carcinoma, Ewing's sarcoma, metastatic breast cancer, brain cancer, neuroendocrine cancer, colon cancer, lung cancer, osteosarcoma, androgen-independent prostate cancer, ovarian cancer, and non-Hodgkin's Lymphoma.

12. The method of claim 1 , wherein said oncological disorder is a non-aggressive oncological disorder.

13. The method of claim 12 , wherein the non-aggressive oncological disorder is selected from the group consisting of non-metastatic breast cancer, androgen-dependent prostate cancer, small cell lung cancer, and acute lymphocytic leukemia.

14. The method of claim 1 , wherein the Coenzyme Q10 is administered by injection or infusion.

15. The method of claim 14 , wherein the Coenzyme Q10 is administered by a route selected from the group consisting of intravenous injection, intravenous infusion, intraperitoneal injection, and intratumoral injection.

16. The method of claim 1 , wherein the Coenzyme Q10 is administered topically.

17. The method of claim 1 , wherein the composition comprises 1% to 25% w/w of the Coenzyme Q10.

18. The method of claim 17 , wherein the composition comprises 1% to 20% w/w of the Coenzyme Q10.

19. A method for blocking anaerobic use of glucose (glycolysis) or augmenting mitochondrial oxidative phosphorylation in a cancer cell, the method consisting of: exposing said cancer cell to a therapeutically effective amount of a composition consisting of 0.001% to 30% w/w of Coenzyme Q10 and one or more pharmaceutically acceptable carriers, wherein the Coenzyme Q10 is supplied in the oxidized form and has a purity between 95% and 100%, to thereby block anaerobic use of glucose or to augment mitochondrial oxidative phosphorylation in said cancer cell, wherein the cancer cell is not a melanoma cell.

20. The method of claim 19 , wherein said cancer cell is in a mammal.

21. The method of claim 20 , wherein said mammal is human.

22. The method of claim 20 , wherein the level of Coenzyme Q10 in the mitochondria of said cancer cell is increased relative to the level of Coenzyme Q10 in the mitochondria of a cancer cell without exposure to said therapeutically effective amount of the composition comprising Coenzyme Q10.

23. The method of claim 19 , wherein the form of the Coenzyme Q10 after entering said cancer cell is maintained as the oxidized form.

Assignees

• Narain Niven Rajin
• Mccook John Patrick
• Sarangarajan Rangaprasad
• Berg Llc

Inventors

• Narain Niven Rajin
• Mccook John Patrick
• Sarangarajan Rangaprasad

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title